Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2019 08:00 ET | Source: Samumed

Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer

SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for SM08502 for the treatment of...
November 19, 2018 08:00 ET | Source: Samumed

Samumed Doses First Subject in Phase 2/3 Trial of SM04554 for the Treatment of Androgenetic Alopecia

SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has dosed the first subject in its phase 2/3 trial of SM04554, a topical small molecule Wnt pathway activator, for...
November 05, 2018 08:00 ET | Source: Samumed

Samumed Announces Multiple Presentations at 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)

SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present clinical and preclinical data on the company’s small molecule Wnt pathway inhibitor, SM04690, in four...
October 24, 2018 08:00 ET | Source: Samumed

Samumed Phase 2b Trial in Knee Osteoarthritis Meets Primary Endpoints

Pivotal phase 3 trials of SM04690 in knee osteoarthritis anticipated to begin early 2019 SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Samumed announced today top-line data from its phase 2b trial...
October 18, 2018 08:00 ET | Source: Samumed

Samumed to Present Preclinical Data on SM07883 at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Congress

SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present preclinical data on the company’s novel DYRK1A inhibitor, SM07883, a potential first-in-class drug for...
October 16, 2018 08:00 ET | Source: Samumed

Samumed to Present Data from Phase 2b Trial of SM04690 for Treatment of Knee Osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting

Top-line Results to be Released as a Late-Breaking Presentation SAN DIEGO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that data will be presented from a phase 2b trial of its...
October 15, 2018 08:00 ET | Source: Samumed

Samumed Announces Sponsorship of Knee Osteoarthritis Registry Study

Collaboration will prospectively evaluate the natural history of knee osteoarthritis progression SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today its sponsorship of a...
August 06, 2018 08:00 ET | Source: Samumed

Samumed Closes on $438 Million in Equity Financing

SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more...
July 27, 2018 08:00 ET | Source: SAMUMED

Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association International Conference® (AAIC®)

Data supports SM07883 as a potential treatment for chronic tauopathies such as Alzheimer’s disease Company expects SM07883 to enter first-in-man studies in fall 2018 SAN DIEGO, July 27, 2018 ...
July 17, 2018 08:00 ET | Source: SAMUMED

Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer’s Disease Candidate, at the Alzheimer’s Association International Conference® (AAIC®) 2018

SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has been selected to present preclinical data on the company’s novel DYRK1a inhibitor, SM07883, a potential...